Raleigh, NC, October 11, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of Odyssey Investment Partners, has been recognized by Everest Group as a Major Contender in its Life Sciences Operations PEAK Matrix® Assessment 2023.
The accolade follows a busy year of growth for ProPharma, including a major launch earlier this year of its Research Consulting Organization (RCO) model, which leads with strategy to de-risk programs and create tailored solutions that help organizations in the biotech, medical device, and pharmaceutical sectors, regardless of their size, confidently introduce new therapies and pursue scientific breakthroughs. Recognized by Inc. 5000 List of America’s Fastest-Growing Companies, ProPharma has also leaned into AI to fasttrack the development of clinical trials and shifted to an AI-first strategy. Through a strategic partnership with H1 to optimize research and development with AI, data insights and analytics, ProPharma and H1 have co-developed ClinCHAT, an AI-powered chatbot that utilizes the latest natural language processing (NLP) and machine learning algorithms to provide a frictionless experience for users navigating complex data queries, regardless of size or development stage.
“We are honored to be named a Major Contender this year, with ProPharma making one of the biggest climbs in placement among all the companies assessed,” said ProPharma Group CEO Michael Stomberg. “This achievement underscores our focus on technology-enabled consulting and delivering comprehensive solutions for our clients. In less than a year after the launch of our Research Consulting Organization model, our team has achieved a number of significant milestones and I’m immensely proud that their hard work has been recognized in this way by Everest Group."
ProPharma was evaluated by Everest Group alongside 27 other leading global life sciences operations providers based on various parameters encompassing their market adoption, portfolio mix, value delivered, vision and strategy, scope of services offered, innovation and investments, and delivery footprint. The assessment by Everest Group consisted of interactions with leading life sciences operations service providers, client reference checks, and an ongoing analysis of the life sciences operations market.
The full report can be viewed here.
###
Zosya Popik
Vice President, Global Marketing
ProPharma
zosya.popik@propharmagroup.com
Jason Wakeford
Associate Partner
Clarity for ProPharma
propharmagroup@clarity.global
The full report can be viewed here.
###
Zosya Popik
Vice President, Global Marketing
ProPharma
zosya.popik@propharmagroup.com
Jason Wakeford
Associate Partner
Clarity for ProPharma
propharmagroup@clarity.global